Publications by Agnieszka Alicja Chryplewicz

Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence

Glioblastoma recurrence is currently inevitable despite extensive standard-of-care treatment. In preclinical studies, an alternative strategy of targeting tumor-associated macrophages and microglia through CSF-1R inhibition was previously found to regress ...

CELL PRESS2024

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor- reactive CD8+T cells and reprogramming macrophages

Douglas Hanahan, Krisztian Homicsko, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz, Stephan Wullschleger

Immunotherapies have shown remarkable, albeit tumor-selective, therapeutic benefits in the clinic. Most pa-tients respond transiently at best, highlighting the importance of understanding mechanisms underlying resistance. Herein, we evaluated the effects o ...

CELL PRESS2023

Elucidating and modulating regulatory pathways so as to reprogram the immunosuppressive tumor microenvironment for therapeutic benefit

Agnieszka Alicja Chryplewicz

Glioblastoma (GBM) is the most frequent and highly malignant form of brain cancer. New therapeutic regimens are urgently needed as GBM patients present with a minimal response to currently-approved therapies. The goal of this project is to identify new the ...

EPFL2023

Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion

Douglas Hanahan, Nadine Fournier, Krisztian Homicsko, Mélanie Louise Tichet, Mohammad Sadegh Saghafinia, Agnieszka Alicja Chryplewicz, Dalya Ataca, Qiqun Zeng, Jeremy Gilles Louis Guillot, Simge Yücel

Many human cancers manifest the capability to circumvent attack by the adaptive immune system. In this work, we identified a component of immune evasion that involves frequent up-regulation of fragile X mental retardation protein (FMRP) in solid tumors. FM ...

American Association for the Advancement of Science2022

Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity

Douglas Hanahan, Krisztian Homicsko, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz, Ksenya Shchors, Julie Laetitia Scotton

Glioblastoma (GBM) is poorly responsive to therapy and invariably lethal. One conceivable strategy to circumvent this intractability is to co-target distinctive mechanistic components of the disease, aiming to concomitantly disrupt multiple capabilities re ...

2022

Agnieszka Alicja Chryplewicz

Graph Chatbot

Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor- reactive CD8+T cells and reprogramming macrophages

Elucidating and modulating regulatory pathways so as to reprogram the immunosuppressive tumor microenvironment for therapeutic benefit

Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion

Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity

Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma

Co-targeting autophagy, macrophages and vasculature in glioma tumors triggers tumor immunity

Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM models

Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor- reactive CD8+T cells and reprogramming macrophages

Elucidating and modulating regulatory pathways so as to reprogram the immunosuppressive tumor microenvironment for therapeutic benefit

Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion

Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity

Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma

Co-targeting autophagy, macrophages and vasculature in glioma tumors triggers tumor immunity

Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM models